Logo image of TRVN

TREVENA INC (TRVN) Stock Fundamental Analysis

NASDAQ:TRVN - Nasdaq - US89532E2081 - Common Stock - Currency: USD

2.5  -2.11 (-45.71%)

After market: 2.39 -0.11 (-4.4%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TRVN. TRVN was compared to 561 industry peers in the Biotechnology industry. Both the profitability and financial health of TRVN have multiple concerns. TRVN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TRVN had negative earnings in the past year.
In the past year TRVN has reported a negative cash flow from operations.
TRVN had negative earnings in each of the past 5 years.
TRVN had a negative operating cash flow in each of the past 5 years.
TRVN Yearly Net Income VS EBIT VS OCF VS FCFTRVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

TRVN's Return On Assets of -264.95% is on the low side compared to the rest of the industry. TRVN is outperformed by 94.16% of its industry peers.
Industry RankSector Rank
ROA -264.95%
ROE N/A
ROIC N/A
ROA(3y)-91.28%
ROA(5y)-69.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRVN Yearly ROA, ROE, ROICTRVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

TRVN has a better Gross Margin (44.36%) than 78.76% of its industry peers.
In the last couple of years the Gross Margin of TRVN has declined.
The Profit Margin and Operating Margin are not available for TRVN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.92%
GM growth 5YN/A
TRVN Yearly Profit, Operating, Gross MarginsTRVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K

More info and screens

3

2. Health

2.1 Basic Checks

TRVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
TRVN has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, TRVN has less shares outstanding
The debt/assets ratio for TRVN is higher compared to a year ago.
TRVN Yearly Shares OutstandingTRVN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M
TRVN Yearly Total Debt VS Total AssetsTRVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -44.49, we must say that TRVN is in the distress zone and has some risk of bankruptcy.
TRVN has a Altman-Z score of -44.49. This is amonst the worse of the industry: TRVN underperforms 93.98% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -44.49
ROIC/WACCN/A
WACC3.98%
TRVN Yearly LT Debt VS Equity VS FCFTRVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

TRVN has a Current Ratio of 3.46. This indicates that TRVN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TRVN (3.46) is worse than 60.88% of its industry peers.
TRVN has a Quick Ratio of 3.46. This indicates that TRVN is financially healthy and has no problem in meeting its short term obligations.
TRVN's Quick ratio of 3.46 is in line compared to the rest of the industry. TRVN outperforms 41.06% of its industry peers.
Industry RankSector Rank
Current Ratio 3.46
Quick Ratio 3.46
TRVN Yearly Current Assets VS Current LiabilitesTRVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

TRVN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -265.62%.
The Revenue has grown by 40.93% in the past year. This is a very strong growth!
Measured over the past years, TRVN shows a very negative growth in Revenue. The Revenue has been decreasing by -11.42% on average per year.
EPS 1Y (TTM)-265.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-733.33%
Revenue 1Y (TTM)40.93%
Revenue growth 3Y0.59%
Revenue growth 5Y-11.42%
Sales Q2Q%-89.24%

3.2 Future

Based on estimates for the next years, TRVN will show a very strong growth in Earnings Per Share. The EPS will grow by 49.93% on average per year.
Based on estimates for the next years, TRVN will show a very strong growth in Revenue. The Revenue will grow by 198.34% on average per year.
EPS Next Y-916.33%
EPS Next 2Y-154.34%
EPS Next 3Y-100.54%
EPS Next 5Y49.93%
Revenue Next Year-95.22%
Revenue Next 2Y63.52%
Revenue Next 3Y-25.99%
Revenue Next 5Y198.34%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TRVN Yearly Revenue VS EstimatesTRVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 0 200M 400M 600M 800M 1B
TRVN Yearly EPS VS EstimatesTRVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TRVN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRVN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRVN Price Earnings VS Forward Price EarningsTRVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRVN Per share dataTRVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A cheap valuation may be justified as TRVN's earnings are expected to decrease with -100.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-154.34%
EPS Next 3Y-100.54%

More info and screens

0

5. Dividend

5.1 Amount

TRVN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TREVENA INC

NASDAQ:TRVN (10/7/2024, 8:23:32 PM)

After market: 2.39 -0.11 (-4.4%)

2.5

-2.11 (-45.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2024-08-08/bmo
Earnings (Next)11-12 2024-11-12/bmo
Inst Owners4.42%
Inst Owner Change-72.73%
Ins Owners1065.78%
Ins Owner Change0%
Market Cap2.13M
Analysts82.5
Price Target102 (3980%)
Short Float %0.4%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.61%
Min EPS beat(2)24.91%
Max EPS beat(2)44.32%
EPS beat(4)2
Avg EPS beat(4)-95.1%
Min EPS beat(4)-275.05%
Max EPS beat(4)44.32%
EPS beat(8)5
Avg EPS beat(8)-33.77%
EPS beat(12)8
Avg EPS beat(12)-19.49%
EPS beat(16)10
Avg EPS beat(16)-15.67%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2400%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1998.85%
EPS NY rev (1m)0%
EPS NY rev (3m)-2027.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1500%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.58
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-16.38
EYN/A
EPS(NY)-20.25
Fwd EYN/A
FCF(TTM)-37.1
FCFYN/A
OCF(TTM)-37.08
OCFYN/A
SpS4.29
BVpS-22.3
TBVpS-22.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -264.95%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.36%
FCFM N/A
ROA(3y)-91.28%
ROA(5y)-69.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.92%
GM growth 5YN/A
F-Score3
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.16%
Cap/Sales 0.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.46
Quick Ratio 3.46
Altman-Z -44.49
F-Score3
WACC3.98%
ROIC/WACCN/A
Cap/Depr(3y)8.27%
Cap/Depr(5y)6.21%
Cap/Sales(3y)3.99%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-265.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-733.33%
EPS Next Y-916.33%
EPS Next 2Y-154.34%
EPS Next 3Y-100.54%
EPS Next 5Y49.93%
Revenue 1Y (TTM)40.93%
Revenue growth 3Y0.59%
Revenue growth 5Y-11.42%
Sales Q2Q%-89.24%
Revenue Next Year-95.22%
Revenue Next 2Y63.52%
Revenue Next 3Y-25.99%
Revenue Next 5Y198.34%
EBIT growth 1Y-46.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y41.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.58%
OCF growth 3YN/A
OCF growth 5YN/A